These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8207292)

  • 1. [Fundamental and clinical studies on MIC breakpoint of SY5555 for Enterococcus faecalis in complicated urinary tract infections of moderate severity].
    Kumamoto Y; Nishimura M; Hirose T; Kamidono S; Arakawa S; Kumazawa J; Matsumoto T
    Kansenshogaku Zasshi; 1994 May; 68(5):639-53. PubMed ID: 8207292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on MIC breakpoint and method of antimicrobial chemotherapy for moderately complicated urinary tract infection--study using an automatic simulator of urinary antimicrobial agent concentrations].
    Nishimura M; Kumamoto Y; Hirose T; Sano M; Ohya S
    Kansenshogaku Zasshi; 1994 Mar; 68(3):366-85. PubMed ID: 8176280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetic, bacteriological, and clinical studies on SY5555 in children].
    Tajima T; Kobayashi M; Hata M; Negishi S; Kubota K; Iitsuka T; Hagiwara N; Kudou S; Nakayama T; Abe T
    Jpn J Antibiot; 1995 Jan; 48(1):31-40. PubMed ID: 7699843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field].
    Toyonaga Y; Ishihara T; Tezuka T; Nakamura H
    Jpn J Antibiot; 1995 Jan; 48(1):71-91. PubMed ID: 7699846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field].
    Motohiro T; Handa S; Yamada S; Oki S; Yoshinaga Y; Oda K; Sakata Y; Kato H; Yamashita F; Imai S
    Jpn J Antibiot; 1995 Feb; 48(2):238-60. PubMed ID: 7745814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activity of gatifloxacin (AM-1155) against Pseudomonas aeruginosa and Enterococcus faecalis in an in vitro bladder model simulating human urinary concentrations after oral administration.
    Takahashi S; Ebisu H; Hirose T; Sano M; Nishimura M; Hirai K; Tsukamoto T; Hosaka M
    Chemotherapy; 2000; 46(2):122-8. PubMed ID: 10671763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for Enterococcus faecalis in complicated community-acquired urinary tract infections in older patients.
    Madrazo M; Esparcia A; Alberola J; Ferrer A; Eiros JM; Nogueira JM; Artero A
    Geriatr Gerontol Int; 2020 Mar; 20(3):183-186. PubMed ID: 31876112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetic and clinical studies on SY5555 dry syrup in children].
    Harada Y; Matsumoto T; Tsuji Y; Gondou I; Kobayashi N; Hayashi K; Uchida T; Uehara Y; Kido T; Fukuda T
    Jpn J Antibiot; 1995 Feb; 48(2):261-70. PubMed ID: 7745815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Laboratory and clinical studies on SY5555 in pediatrics].
    Iwai N; Nakamura H
    Jpn J Antibiot; 1995 Jan; 48(1):103-28. PubMed ID: 7699834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical studies on SY5555 in pediatric infections].
    Niinou K; Sigeta M; Kuwahata K; Suzuki H; Sato H
    Jpn J Antibiot; 1995 Jan; 48(1):49-70. PubMed ID: 7699845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetic and clinical studies of SY5555 in the pediatric field. Pediatric Study Group of SY5555].
    Fujii R; Abe T; Tajima T; Terashima I; Meguro H; Sato H; Niino K; Suzuki H; Toyonaga Y; Nakamura H
    Jpn J Antibiot; 1994 Apr; 47(4):383-408. PubMed ID: 8201768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies on SY5555 in the field of pediatrics].
    Kitamura K; Ihara T; Kamiya H; Nakano T; Itoh M; Sakurai M
    Jpn J Antibiot; 1995 Jan; 48(1):133-9. PubMed ID: 7699836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fundamental and clinical studies of SY5555 in pediatrics].
    Yokota T; Akita H; Sato Y; Iwata S; Sunakawa K
    Jpn J Antibiot; 1995 Jan; 48(1):92-102. PubMed ID: 7699847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and laboratory studies on SY5555 in pediatric infectious diseases].
    Wakiguchi H; Nagao A; Watanabe S; Okada T; Hamada F; Kurashige T
    Jpn J Antibiot; 1995 Feb; 48(2):229-37. PubMed ID: 7745813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
    Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative studies on activities on antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2000). III. Secular changes in susceptibility].
    Kumamoto Y; Tsukamoto T; Hirose T; Matsukawa M; Takahashi S; Kunishima Y; Fujime M; Fujita K; Ogihara M; Ishibashi K; Igari J; Shigeta S; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Yoshida H; Imafuku Y; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Kitamura M; Takano Y; Matsuoka Y; Matsuda S; Sato S; Furuhama T; Kumon H; Monden K; Kohno S; Miyazaki Y; Tomono K; Aoki S; Mochida C; Hirakata Y
    Jpn J Antibiot; 2002 Oct; 55(5):568-655. PubMed ID: 12532638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal effect of levofloxacin on strains with equal susceptibility in an in vitro urinary bladder model.
    Takahashi S; Sano M; Nishimura M; Matsukawa M; Mikami M; Hirose T; Tsukamoto T
    Chemotherapy; 1998; 44(5):337-42. PubMed ID: 9732150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.